Next Article in Journal
Prevalence and Genotyping of High Risk Human Papillomavirus in Cervical Cancer Samples from Punjab, Pakistan
Next Article in Special Issue
Virus-Vectored Influenza Virus Vaccines
Previous Article in Journal
Increased Plasma Cell-Free DNA Level during HTNV Infection: Correlation with Disease Severity and Virus Load
Previous Article in Special Issue
RNA Virus Reverse Genetics and Vaccine Design
Article Menu

Export Article

Open AccessReview
Viruses 2014, 6(7), 2735-2761; doi:10.3390/v6072735

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases

1
Department of Viroscience, Erasmus Medical Center (EMC), P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
2
Institute for Infectious Diseases and Zoonoses, LMU, University of Munich, 80539, Munich, Germany
*
Authors to whom correspondence should be addressed.
Received: 30 April 2014 / Revised: 25 June 2014 / Accepted: 25 June 2014 / Published: 17 July 2014
(This article belongs to the Special Issue Virus-based Vaccines)
View Full-Text   |   Download PDF [827 KB, uploaded 12 May 2015]   |  

Abstract

Respiratory viruses infections caused by influenza viruses, human parainfluenza virus (hPIV), respiratory syncytial virus (RSV) and coronaviruses are an eminent threat for public health. Currently, there are no licensed vaccines available for hPIV, RSV and coronaviruses, and the available seasonal influenza vaccines have considerable limitations. With regard to pandemic preparedness, it is important that procedures are in place to respond rapidly and produce tailor made vaccines against these respiratory viruses on short notice. Moreover, especially for influenza there is great need for the development of a universal vaccine that induces broad protective immunity against influenza viruses of various subtypes. Modified Vaccinia Virus Ankara (MVA) is a replication-deficient viral vector that holds great promise as a vaccine platform. MVA can encode one or more foreign antigens and thus functions as a multivalent vaccine. The vector can be used at biosafety level 1, has intrinsic adjuvant capacities and induces humoral and cellular immune responses. However, there are some practical and regulatory issues that need to be addressed in order to develop MVA-based vaccines on short notice at the verge of a pandemic. In this review, we discuss promising novel influenza virus vaccine targets and the use of MVA for vaccine development against various respiratory viruses. View Full-Text
Keywords: modified vaccinia virus ankara; vaccine development; influenza virus; respiratory syncytial virus; parainfluenza virus; coronavirus modified vaccinia virus ankara; vaccine development; influenza virus; respiratory syncytial virus; parainfluenza virus; coronavirus
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Altenburg, A.F.; Kreijtz, J.H.C.M.; de Vries, R.D.; Song, F.; Fux, R.; Rimmelzwaan, G.F.; Sutter, G.; Volz, A. Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases. Viruses 2014, 6, 2735-2761.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top